Novocure GmbH
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Device: NovoTTF-200T
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 69
- Registration Number
- NCT06558799
- Locations
- 🇫🇷
Montpellier University Hospital, Montpellier, France
🇪🇸ClÃnica Universidad de Navarra, Madrid, Madrid, Spain
🇪🇸ClÃnica Universidad de Navarra, Pamplona, Spain
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 741
- Registration Number
- NCT06556563
- Locations
- 🇬🇧
Addenbrooke's Hospital (Cambridge University Hospitals NHS Foundation Trust), Cambridge, United Kingdom
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 734
- Registration Number
- NCT06216301
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇦🇹Karl Landsteiner Institut fur Lungenforschung und pneumologische Onkologie c/o Klinik Floridsdorf, Vienna, Austria
🇧🇪Cliniques universitaires Saint-Luc, Brussels, Belgium
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
- Conditions
- Pleural Mesothelioma
- Interventions
- Device: TTFields
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 198
- Registration Number
- NCT05538806
- Locations
- 🇩🇪
Kliniken der Stadt Koeln, Cologne, Germany
🇩🇪Florence-Nightingale-Hospital, Düsseldorf, Germany
🇩🇪Klinikum Essen-Mitte, Essen, Germany
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge
- Conditions
- COVID-19
- Interventions
- Device: NovoTTF-100L
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT04953234
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Device: NovoTTF-200T
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 15
- Registration Number
- NCT04892472
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Palo Verde Cancer Specialists, Glendale, Arizona, United States
🇺🇸UCHealth Memorial Hospital, Colorado Springs, Colorado, United States
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
- Conditions
- Glioblastoma Multiforme
- Interventions
- Device: TTFields
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT04492163
- Locations
- 🇨🇿
Nemocnice Na Homolce, Prague, Czechia
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
- Conditions
- Nonsmall Cell Lung CancerNSCLC
- Interventions
- Device: NovoTTF-200TDrug: Immune checkpoint inhibitors or docetaxel
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 276
- Registration Number
- NCT02973789
- Locations
- 🇺🇸
Clinical Oncology Associates, Farmington Hills, Michigan, United States
🇺🇸Dallas VA Medical Center, Dallas, Texas, United States
🇺🇸Renown Regional Medical Center Institute for Cancer, Reno, Nevada, United States
Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).
- Conditions
- Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Device: NovoTTF-200M deviceOther: Best Standard of Care
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 298
- Registration Number
- NCT02831959
- Locations
- 🇺🇸
Piedmont Brain Tumor Center, Atlanta, Georgia, United States
🇺🇸Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States